Preventing HBV Infection with ART

Antiretroviral regimens containing 3TC, tenofovir, or both, reduced the risk for incident hepatitis B virus infection by approximately 90% compared with other or no antiretrovirals.

Hepatitis B virus (HBV) coinfection is common in HIV-infected individuals, particularly men who have sex with men (MSM). Tenofovir, 3TC, and FTC have clinically relevant anti-HBV activity, which has been demonstrated in prospective trials. Whether these agents might prevent incident HBV infection has not been examined previously.

To explore this issue, researchers in Japan evaluated sequential samples from HIV-infected MSM who had serum stored between April 1997 and December 2009 and had no detectable HBV surface antigen or antibodies to HBV surface or core proteins at baseline. Evidence of HBV infection was detected in follow-up samples from 43 of the 354 men (12.1%) after a median of 1.6 years (range, 28–4068 days). The rate of incident in…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Preventing HBV Infection with ART

Topics

Reviewing Author